Antiviral prophylaxis of smallpox

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 1, 2004, Pages 1-5

  Bray, Mike ^a   Roy, Chad J ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Aerosol therapy; Airborne infections; Antiviral therapy; Biodefence; Cidofovir; Monkeypox; Vaccination

Indexed keywords

ALKANOL; ANTIVIRUS AGENT; CIDOFOVIR; ETHER; SMALLPOX VACCINE;

AEROSOL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG ABSORPTION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RETENTION; GASTROINTESTINAL ABSORPTION; INFECTION PREVENTION; LUNG PARENCHYMA; NEPHROTOXICITY; NONHUMAN; POXVIRUS; PROVOCATION TEST; SMALLPOX;

ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; CYTOSINE; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; SMALLPOX; SMALLPOX VACCINE; VACCINATION;

EID: 3543130710     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh286     Document Type: Article

References (27)

1. Heiner, G., Fatima, N., Russell, P. et al. (1971). Field trials of methisazone as a prophylactic agent against smallpox. American Journal of Epidemiology 94, 435-49.
2. Fenner, F., Henderson, D., Arita, I., et al. (1988). Smallpox and its Eradication. World Health Organization, Geneva, Switzerland.
3. De Clercq, E., Neyts, J. & Clercq, E. D. (2003). Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antiviral Research 57, 25-33.
4. Baker, R., Bray, M. & Huggins, J. (2003). Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Research 57, 13-23.
5. Bray, M. & Buller, R. (2004). Looking back at smallpox. Clinical Infectious Diseases 38, 882-9.
6. Bray, M. (2003). Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Research 58, 101-14.
7. Jackson, R., Ramsay, A., Christensen, C. et al. (2001). Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. Journal of Virology 75, 1205-10.
8. Osterhaus, A. & de Jong, J. (1999). The control of influenza: antivirals as an adjunct to vaccines. Vaccine 18, 779-80.
9. Monto, A. (2003). The role of antivirals in the control of influenza. Vaccine 21, 1796-800.
10. Bray, M., Martinez, M., Kefauver, D. et al. (2002). Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Research 54, 129-42.
11. Roy, C., Baker, R., Washburn, K. et al. (2003). Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge. Antimicrobial Agents and Chemotherapy 47, 2933-7.
12. Kern, E., Hartline, C., Harden, E. et al. (2002). Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrobial Agents and Chemotherapy 46, 991-5.
13. Ciesla, S., Trahan, J., Wan, W. et al. (2003). Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Research 59, 163-71.
14. Aldern, K., Ciesla, S., Winegarden, K. et al. (2003). Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Molecular Pharmacology 63, 678-81.
15. Quenelle, D., Collins, D., Wan, W. et al. (2004). Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrobial Agents and Chemotherapy 48, 404-412.
16. Buller, R., Owens, G., Schriewer, J. et al. (2004). Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318, 474-81.
17. Neyts, J. & De Clercq, E. (1993). Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. Journal of Medical Virology 41, 242-6.
18. Bray, M., Martinez, M., Smee, D. et al. (2000). Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. Journal of Infectious Diseases 181, 10-9.
19. Smith, K. & Skelton, H. (2002). Molluscum contagiosum: recent advances in pathogenic mechanisms, and new therapies. American Journal of Clinical Dermatology 3, 535-45.
20. Geerinck, K., Lukito, G., Snoeck, R. et al. (2001). A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. Journal of Medical Virology 64, 543-9.
21. Smee, D., Sidwell, R., Kefauver, D. et al. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrobial Agents and Chemotherapy 46 1329-35
22. Ho, H., Woods, K., Bronson, J. et al. (1992). Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonyl-methoxy)propyl]cytosine. Molecular Rharmacology 41, 197-202.
23. Hao, Z., Stowe, E., Ahluwalia, G. et al. (1993). Characterization of 2,3-dideoxycytidine diphosphocholine and 2,3-dideoxycytidine diphosphoethanolamine. Prominent phosphodiester metabolites of the anti-HIV nucleoside 2,3-dideoxycytidine. Drug Metabolism and Disposition 21, 738-44.
24. Cundy, K. (1999). Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clinical Pharmacokinetics 36, 127-43.
25. Snoeck, R., Wellens, W., Desloovere, C. et al. (1998). Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. Journal of Medical Virology 54, 219-25.
26. Smee, D., Bailey, K. & Sidwell, R. (2004). Topical cidofovir is more effective than parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. Journal of Infectious Diseases 190, in press.
27. Sutter, G. & Staib, C. (2003). Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Current Drug Targets for Infectious Disorders 3, 263-71.